The single biggest decision you will make when choosing a GLP-1 provider is not which company to use — it is whether to take a compounded medication or a brand-name one. The price difference is enormous, often three to ten times. The products are not the same, and the trade-offs are more nuanced than either the marketing or the scare stories suggest. Here is what compounding actually is, what changed when the shortages ended, and how to weigh the decision honestly.
What compounding actually means
A compounding pharmacy prepares a medication for a specific patient rather than manufacturing a standardised product at scale. It is a long-established part of medicine — compounding exists so that a child can get a liquid version of a tablet, or a patient allergic to a dye can get the same drug without it.
Compounded semaglutide and tirzepatide are prepared by pharmacies using the active pharmaceutical ingredient rather than being made by Novo Nordisk or Eli Lilly. The molecule is intended to be the same. The manufacturing process, quality control, testing regime, and regulatory oversight are not.
The core distinction
Compounded drugs are not FDA-approved. That does not mean they are illegal or that compounding pharmacies are unregulated — pharmacies are licensed and inspected by state boards, and 503B outsourcing facilities are registered with the FDA. It means no regulator has reviewed the specific product for safety, efficacy, and manufacturing consistency the way it did for Wegovy or Zepbound.
Why compounded GLP-1s became so common
When semaglutide and tirzepatide were placed on the FDA drug shortage list, compounding pharmacies were permitted to prepare copies to meet demand the manufacturers could not. An entire industry grew up around that allowance, and hundreds of telehealth platforms were built on it.
When the shortages were declared resolved, the legal basis for large-scale compounding of these specific molecules narrowed substantially. The market has been in flux ever since, with regulators intensifying scrutiny and some platforms shifting toward brand-name products or toward formulations they argue remain permissible.
The practical consequence for patients is that the compounded market carries a regulatory risk brand-name medication does not. A supply you rely on can become unavailable for reasons that have nothing to do with your clinical situation — and food noise returns reliably when treatment lapses.
The price difference, honestly stated
The gap is real and large. These figures move constantly, but the shape of the market has been broadly consistent.
| Route | Typical monthly cost | FDA-approved |
|---|---|---|
| Compounded semaglutide | $99–$299 | No |
| Compounded tirzepatide | $133–$399 | No |
| Brand self-pay (manufacturer direct) | $299–$499 | Yes |
| Brand via retail pharmacy, uninsured | $1,000–$1,400 | Yes |
| Brand with insurance coverage | $0–$100 copay | Yes |
The row people miss is the last one. If your insurance covers a GLP-1, brand-name medication is almost always cheaper than compounded — often dramatically so. Before choosing a cash-pay compounded platform, find out what your plan actually covers, because a $25 copay beats every compounded price in this table.
What the quality question really turns on
Compounded GLP-1s vary enormously in quality, and the variation is between pharmacies rather than inherent to compounding. A well-run 503B facility performing sterility and endotoxin testing on every batch is a different proposition from an operation nobody has audited.
The problem for patients is visibility. Most telehealth platforms will not tell you which pharmacy fills your prescription, which means you cannot evaluate the thing that actually matters.
- Ask which pharmacy compounds your medication, by name.
- Ask whether sterility and endotoxin testing is performed on every batch.
- Ask whether the pharmacy is a 503A pharmacy or a 503B outsourcing facility.
- Be wary of combination products — semaglutide with B12, glycine, or L-carnitine — where the evidence for the added ingredients is far weaker than for the GLP-1 itself.
- Treat any platform that will not answer these questions as having answered them.
Dose consistency and why it matters for food noise
This is the practical argument for brand-name medication that gets discussed least. Food noise relief is dose-dependent — most patients identify a threshold dose at which the mental chatter drops away rather than merely diminishing.
Finding that threshold requires knowing what you actually took. With brand-name Wegovy or Zepbound, a 7.5 mg dose is a 7.5 mg dose, manufactured to a standard, every time. With compounded preparations, concentration varies between pharmacies and formulations, and a plateau becomes ambiguous: do you need a higher dose, or is this batch weaker than the last?
Patients switching from compounded to brand-name products very often remark on this specifically — not that the effect is stronger, but that it is predictable.
How to decide
- 1
Check your insurance first
Find out whether your plan covers any GLP-1 and what the prior authorisation criteria are. If it does, brand-name medication through your benefit is almost certainly your cheapest and safest route, and it is worth pursuing an appeal if you are initially denied.
- 2
If uninsured, price the manufacturer channels
Eli Lilly and Novo Nordisk both sell direct to self-pay patients at a few hundred dollars a month — far below retail and within reach of what several compounded platforms charge once membership fees are included.
- 3
If compounded is the only affordable route, choose carefully
Prefer platforms that name their pharmacy, publish testing practices, and price flat rather than escalating with dose. Avoid combination formulations where the additions have no evidence behind them.
- 4
Plan for regulatory disruption
The compounded market has been repeatedly disrupted. Know what your fallback is before you need it, because an interruption in supply will bring your food noise back.
- 5
Revisit the decision periodically
Prices in this market change constantly and manufacturer self-pay programs have generally been getting cheaper. The calculation you made a year ago may no longer hold.
Key Takeaways
- →Compounded GLP-1s are not FDA-approved products — that is a real distinction, not marketing.
- →If your insurance covers a GLP-1, brand-name medication is almost always cheaper than any compounded option.
- →Manufacturer direct-pay channels have narrowed the gap considerably for uninsured patients.
- →Quality varies between compounding pharmacies, not inherently by compounding — ask which pharmacy fills your prescription.
- →Dose consistency matters specifically for food noise, because relief arrives at a threshold dose you need to be able to identify.
- →The compounded market carries regulatory risk that can interrupt your supply for reasons unrelated to your health.
Frequently Asked Questions
Is compounded semaglutide the same as Wegovy?+
It is intended to contain the same active molecule, but it is not the same product. Wegovy is manufactured by Novo Nordisk under FDA-approved processes with regulated quality control. Compounded semaglutide is prepared by a pharmacy without that approval or oversight of the specific product.
Is compounded semaglutide safe?+
Quality varies substantially between pharmacies. A well-run facility performing sterility and endotoxin testing on every batch is a very different proposition from one that does not. The problem is that most patients cannot see which they are getting, which is why asking your platform to name its pharmacy matters.
Why is compounded medication so much cheaper?+
It avoids the costs of the FDA approval process, brand marketing, and the pricing structure built around patented products. That is genuinely why it is cheaper — but the savings come from skipping the regulatory apparatus, which is precisely what you are giving up.
Will compounded GLP-1s stay available?+
This is uncertain. The legal basis for large-scale compounding narrowed when the official shortages were declared resolved, and regulatory scrutiny has intensified. Patients relying on compounded supply should know what their fallback is, since an interruption brings food noise back.
What about combination formulations with B12 or glycine?+
These are common in the compounded market. The evidence for the added components is considerably weaker than for the GLP-1 itself, which is what does the work on appetite and food noise. They are not usually harmful, but do not pay a premium for them.
Should I switch from compounded to brand-name?+
Check your insurance first — if you have coverage, brand-name is likely cheaper as well as FDA-approved. If you are uninsured, compare manufacturer direct-pay pricing against your current all-in compounded cost including any membership fee. The gap is smaller than most people assume.
Looking for a provider?
We have reviewed 167 GLP-1 providers and ranked them by category:
Related Reading
This article is educational content, not medical advice. GLP-1 medications require a prescription and clinical supervision — talk to a licensed clinician about whether treatment is appropriate for you. See our medical disclaimer.